A Study of RD14-01 in Patients With Advanced Solid Tumors
This study will evaluate the safety and tolerability of RD14-01, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ advanced solid tumors.
Solid Tumor
BIOLOGICAL: RD14-01
DLT and MTD, Dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), up to 28 days after infusion|TEAEs, Adverse events (TEAEs) and incidence after the first infusion, treatment-related adverse events and incidence, adverse events of special concern (AESI) and incidence, up to 12 months after infusion
ORR, Overall Response Rate (ORR) by RECIST, version 1.1, up to 28 days after infusion|DOR, Duration of response (DOR), up to 12 months after infusion|PFS, Progression Free Survival(PFS), up to 12 months after infusion|OS, Overall Survival (OS), up to 12 months after infusion|Maximum concentration of RD14-01 (Cmax) in peripheral blood (PB) samples, Maximum concentration of RD14-01 (Cmax) in peripheral blood (PB) samples, up to 12 months after infusion|Persistence of RD14-01 CAR T cells in peripheral blood samples, Persistence of RD14-01 CAR T cells in peripheral blood samples, up to 12 months after infusion
This single-arm, open-label, dose-escalation and dose-expansion study will evaluate the safety and tolerability of RD14-01, ROR1-targeting CAR T cells, in adults with ROR1+ advanced solid tumors.